Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata

This article was originally published here

Topline data from this dose regimen trial is expected in the first half of 2020. “We are extremely grateful to the patients who volunteer to participate in our

The post Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply